USFDA clears first oral treatment for alpha, beta thalassaemia

After decades, adults living with thalassaemia-related anaemia now have an oral alternative. The USFDA has approved mitapivat, sold as Aqvesme, the first pill designed to treat anaemia in people with alpha or beta thalassaemia, a common inherited blood disorder. The condition is passed down through families, in which faulty genes limit the body’s ability to produce healthy haemoglobin.